Tag: biopharma
-
![ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%]()
ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70%
A Need for Alternatives $54.898M Market Capitalization ERYTECH Pharma (ERYP.Q) announced today that the Company has sold its US manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies. Under the terms of the agreement, Catalent has agreed to purchase ERYTECH’s US facility for a total consideration of $44.5 million. That’s…
-
![Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)]()
Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical…
-
![Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem]()
Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she points at her purse and mimes the universal L-shaped hand pattern for an asthma inhaler. She sits while you go digging through spent candy wrappers, old…
-
![Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal]()
Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according to a press release. The terms of the agreement give Bioasis the ability to issue convertible securities up to $10 million with proceeds going to general…
-
Vinergy Resources (VIN.C) finally kills off long fruitless deal with MJ Biopharma
They won’t tell us why, but the long drawn out change of business deal with MJ Biopharma that was being engaged in by Vinergy Resources (VIN.C) is over as of today. Why did this happen? God, it could be any number of things. MJ Biopharma’s principals may not have passed due diligence, the business case…
